Executive Burnout Psychedelic Therapy: What the Research Shows
Executive burnout psychedelic therapy is moving from the research margins into serious clinical conversation. A growing body of peer-reviewed evidence suggests that psilocybin-assisted therapy can reduce...
Psilocybin Alcohol Use Disorder: What Hopkins and NYU Research Found
Research on psilocybin alcohol use disorder treatment, including a landmark 2022 randomized controlled trial published in JAMA Psychiatry, has shown meaningful reductions in heavy drinking days...
Psychedelics and Creativity: What Executives Need to Know
Interest in psychedelics and creativity among executives has moved well beyond Silicon Valley. Neuroscientific research points to measurable changes in divergent thinking, cognitive flexibility, and problem-solving...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
The default mode network, explained: why psychedelics reset how your brain thinks
The default mode network is a cluster of brain regions responsible for self-referential thinking, rumination, and your ongoing sense of “I.” Research on default mode network...
What executives are actually using psychedelic therapy for (and what the data shows)
Psychedelic therapy for executives is moving beyond reputation and into clinical evidence. A growing number of C-suite leaders are using professionally supported psilocybin and ketamine experiences...
Psychedelics for Depression: What the 2026 Research Actually Shows
Quick Answer Psilocybin and other psychedelics show real, measurable promise for depression, particularly treatment-resistant cases. But the evidence in 2026 is more complicated, more honest, and...
Microdosing Psychedelics — Promise, Risks, and Where We Go from Here
Quick answer: Microdosing psychedelics means taking very small, sub-perceptual doses of substances such as psilocybin or LSD, usually on a repeated schedule rather than in a...
LSD for Anxiety: What a Landmark Clinical Trial Actually Found
Quick answer: A LSD For Anxiety randomized, placebo-controlled Phase 2b trial published in JAMA found that a single oral dose of MM120, an investigational LSD formulation...
MDMA Therapy FDA Decision, What the Rejection Letter Means for Seekers
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, citing three specific concerns: gaps in safety reporting, insufficient evidence that benefits lasted over time,...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.